The Market For Diabetes Drugs, Devices, And Disease Man...

The Market For Diabetes Drugs, Devices, And Disease Management

The Market For Diabetes Drugs, Devices, And Disease Management

Published Date: May 1996
Published By: Kalorama Information
Page Count: 214
Order Code: R566-215
Attention: There is an updated edition available for this report.

$3,500.00 Online Download
$3,500.00 Hard Copy Mail Delivery
$7,000.00 Global Site License
$3,800.00 Online Download plus 1 Hard Copy

Description

The current market for diabetes products is large and growing. Both monitoring and therapeutic products have an excellent market outlook. Diabetes markets have long had major areas of unmet need, and that has not changed during the past several decades. In fact, the number of diabetic patients, especially in the United States, will increase at an accelerating rate over the next 20 years. With the recognition of diabetes as a public health issue of increasing importance, greater pressure will be placed on the medical products industry to satisfy those needs.
So significant is the market opportunity that young companies—many small biopharmaceutical firms—are springing up to meet this challenge, dedicating their entire R&D efforts to diabetes alone. New technologies and drug classes for the treatment of diabetes are being developed, as are methods of diabetes prevention for at-risk populations. It is a market brimming with opportunities and seeing increasing competition for those opportunities.

In such a dynamic marketplace, an understanding of the players and the playing field is an absolute necessity for any company active in diabetes product development, manufacture, and marketing. This completely revised and re-researched edition of Kalorama’s popular 2002 report is intended to provide the pertinent information vital to the serious competitors in the diagnostic and therapeutic diabetes marketplace.

This study considers diagnostics and therapeutics for diabetes type 1 and type 2, as well as the therapeutic markets for several long-term complications of diabetes including hypertension, dyslipidemia, cardiovascular disease, and vascular disorders (retinopathic, neuropathic, renal, and podiatric). The study details the top seven world markets in terms of epidemiology, market potential, and clinical and business trends. In addition new technologies are reviewed and competitors are profiled. Major conclusions of the study are presented with strategic implications and recommendations.

For this edition, a completely new chapter on nutritional and herbal supplementation approaches to diabetes examines the market presence of these new alternative products and their impact on traditional markets.

CHAPTER ONE: EXECUTIVE SUMMARY

Background
Scope and Methodology
Size and Growth of Market
The Nature of the Industry
The New Technologies
Market Trends

CHAPTER TWO: INTRODUCTION
The Pathology of Diabetes and Its Complications
Diabetes
Type I Diabetes
Type II Diabetes
Gestational Diabete<,/UL>
Long-Term Complications
Hypertension
Dyslipidemia
Cardiovascular Disease
Vascular Complications
Diabetic Retinopathy
Renal Complications
Neuropathies
Diabetic Foot
Epidemiology
France
Germany
Italy
Japan
Spain
United Kingdom
United States
CHAPTER THREE: DIABETES MONITORING

Background
Glucose Monitoring
Animas Corp.
Argose Inc.
Biocontrol Technology Inc.
CIBA Vision
CME Telemetrix Inc.
DexCom Inc.
Diabetech Ltd. Co.
Diabetex International Corp.
Fluent Biomedical Corp.
Foviopitics Inc.
GlucoLight Corporation
Glucon Medical Ltd.
Gluko MediTech AG
GluMetrics LLC
GlySens Inc.
Hitachi Ltd.
HypoGuard USA Inc.
Infratec Inc.
InLight Solutions Inc.
Institut für Chemo- und Biosensorik
Integrity Applications
International Diagnostic Technologies Inc. (IDT)
iSense Corp
Kumetrix Inc.
LifeTrac Systems Inc.
LighTouch Medical Inc.
MedOptix Inc.
MicroSense International LLC
Mystic Medical Devices (MMD)
OptiScan Biomedical Corp.
OrSense Ltd.
Pelikan Technologies Inc.
Pendragon Medical Ltd.
Phoenix Bioscience
Pindi Products
PowderChek Diagnostics
PreciSense
Sensors for Medicine and Science Inc. (SMSI™)
Sensys Medical
Sontra Medical Inc.
SpectRx Inc.
Synthetic Blood International
TecMed Inc.
TheraSense Inc.
Visionary Medical Products Corporation

Hemoglobin A1C (HbA1C)
Ketone Monitoring
Microalbumin Monitoring
CHAPTER FOUR: CURRENT THERAPEUTIC APPROACHES

Background
Therapeutic Practices
France
Diabetes
Complications

Germany
Diabetes
Complications

Italy
Diabetes
Complications3

Japan
Diabetes
Complication

Spain
Diabetes
Complications

United Kingdom
Diabetes
Complications

United States
Diabetes
Complications

Current Therapeutics for Diabetes
Insulin
Oral Hypoglycemics
Sulfonylureas
Biguanides
&#945;-Glucosidase Inhibitors
Thiazolidinediones
Meglitinides
D-Phenylalanine Derivatives


Current Therapeutics for Diabetic Complications
Antihypertensive Therapy
ACE Inhibitors
&#945;/&#946;(Alpha/Beta)-Blockers
Calcium Channel Blockers
Diuretics
Angiotensin II Receptor Antagonists

Dyslipidemia Therapy
Atherosclerosis Therapy
Arrhythmia Therapy
Peripheral Vascular Disease Therapy
CHAPTER FIVE: MONITORING AND THERAPEUTICS MARKETS

Background
Market Status and Segmentation
Monitoring
Therapeutics
Insulin
Oral Hypoglycemics

Diabetic Complication Drugs

Geographic Markets
France
Germany
Italy
Japan
Spain
United Kingdom
United States
CHAPTER SIX: NUTRITIONAL SUPPLEMENT AND HERBAL APPROACHES TO THE TREATMENT OF DIABETES

Background
Nutritional Supplements
Ascorbic Acid (Vitamin C)
Biotin
Chromium
Copper
Magnesium
Niacin and Niacinamide
Potassium
Selenium
Thiamine
Vanadium
Vitamin B6
Vitamin B12
Vitamin E
Zinc


Nutritional Treatment of Diabetic Neuropathy
Herbal Treatment of Diabetes
Aloe (Various)
Arctium lappa (Burdock Root)
Allium cepa (Onion)
Grifola frondosa (Maitake Mushroom)
Mulberry
Panax ginseng (Korean ginseng)


Ayurvedic Medicine and Herbs
Gymnema sylvestre (Asclepias germinata)
Momordica charantia (Bitter Gourd)
Trigonella foenum graecum (Fenugreek)


Other herbs with Significant Anti-Diabetic Effects
Traditional Chinese Medicine
CHAPTER SEVEN: FORWARD-LOOKING TECHNOLOGIES


Background
Beta-Cell Transplantation Research
Research Activities
CHAPTER EIGHT: COMPANY PROFILES


Abbott Laboratories
Abgenix, Inc.
Alkermes
Amylin Pharmaceuticals
AstraZeneca
Aventis Pharma US Division of Aventis
The Bayer Group (USA) Subsidiary of Bayer AG
BresaGen Limited
Bristol-Myers Squibb
Calyx Therapeutics Inc.
Diabetogen Biosciences, Inc.
GlaxoSmithKline
Eli Lilly & Co.
Metabolex, Inc.
MitoKor
Neurocrine Biosciences
Novo Nordisk
O.S.I. Pharmaceuticals
Pfizer Inc.
Takeda Pharmaceuticals North America
Telik, Inc.
Transition Therapeutics, Inc.